RecruitingPhase 2NCT04830267

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Studying Best vitelliform macular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chongqing University Cancer Hospital
Principal Investigator
Ying Wang, Ph.D, M.D.
Chongqing University Cancer Hospital
Intervention
Camrelizumab(drug)
Enrollment
39 target
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04830267 on ClinicalTrials.gov

Other trials for Best vitelliform macular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Best vitelliform macular dystrophy

← Back to all trials